Sienna Cancer Diagnostics Ltd

A Vipep Pty Limited

Fabio Turatti

Peter John Hudson

Debra Tamvakis

Minesh Lalla

Sharyn Wilson

Michael P Wheatcroft

Michael Paul Wheatcroft

Paul R Sanders

David Leong

Paul Robert Sanders

The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of an antibody binding to a diagnostic protein in the clinically relevant cells in the sample.

Method of detecting cancer

The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of antibody binding to telomerase in clinically relevant cells in the sample, wherein binding of the antibody to clinically relevant cells indicates the presence of malignant or cancerous cells.

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region (FR) 2 and/or at least two cysteine residues positioned within framework region (FR3), wherein if at least two of the cysteine residues in FR2 and/or FR3 are not conjugated to a compound then an intra-framework disulphide bond is capable of forming between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region (V) and an immunoglobulin light chain variable region (V), wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides conjugates of the protein and another compound.

Immuno-conjugates and methods for producing them

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.

Growing community of inventors

Docklands, Australia

Fabio Turatti